Repare Therapeutics RPTX 深 滬
已收盤 09-12 16:00:00 美东时间
1.76
-0.050
-2.76%
華盛通- 最 高1.82
- 今 開1.82
- 成交量 9.04万股
- 最 低 1.73
- 昨 收 1.81
- 總市值 7560.82万
- 52周最高 4.0695
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 0.89
- 委 比 -31.30%
- 總股本 4295.92万
- 歷史最高 46.44
- 量 比 0.78
- 振 幅 4.97%
- 歷史最低 0.89
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics announced that its management will participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, focused on developing precision medicines for neurological and psychiatric disorders, will host a fireside chat during the virtual event. Investors can access the webcast on the company’s website. Rapport’s RAP technology platform enables the creation of targeted sma...
09-11 20:05
Rapport Announces Proposed Public Offering of Common Stock
Rapport Therapeutics is conducting a $250 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions and has been filed with the SEC under a shelf registration statement. Rapport Therapeutics focuses on developing small molecule precision medicines for neurological and psychiatric disorders, utilizing its RAP technology platform to...
09-08 20:05
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics将举行电话会议和网络直播，于9月8日上午8点ET，公布RAP-219治疗难治性局灶性癫痫的IIa期顶线结果。公司聚焦神经及精神疾病精准药物，RAP技术基于受体蛋白，使药物如RAP-219精准作用于大脑特定区域，用于治疗癫痫、双相情感障碍和神经痛等。
09-05 20:05
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
reAlpha Tech Corp. Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
reAlpha Tech Corp. announced the purchase and sale of 14,285,718 shares of its common stock at $0.35 per share in a registered direct offering under Nasdaq rules. Concurrently, the company will issue unregistered warrants for up to 14,285,718 shares with an exercise price of $0.35 per share, exercisable immediately and expiring in five years. The offering is expected to close on July 22, 2025, subject to customary closing conditions. H.C. Wainwri...
07-21 20:30
Repare Therapeutics shares are trading higher after the company entered a licensing agreement with Debiopharm for Lunresertib.
Repare Therapeutics shares are trading higher after the company entered a licen...
07-16 04:11
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics announced the addition of Scott Braunstein, M.D., to its Audit Committee and Ashley Dombkowski, Ph.D., to its Nominating and Corporate Governance Committee. Both bring extensive industry experience. RAPT’s lead product, RPT904, a novel monoclonal antibody targeting free IgE, is completing Phase 2 trials in chronic spontaneous urticaria and asthma, with plans for a Phase 2 study in food allergy later this year. The company aims t...
06-23 12:00
Repare Therapeutics Updates Severance Benefits for Executives
Repare Therapeutics ( ($RPTX) ) has issued an announcement. On June 13, 2025, R...
06-21 04:42
12款小分子新药化学结构首次公开
转自：中国医药报 在前不久美国化学会（ACS）举行的2025春季会议上，12款已进入或即将进入临床试验的小分子药物的化学结构首次公开亮相，这些潜在的新药适应证...
06-19 08:18
